"Cell Line, Tumor" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A cell line derived from cultured tumor cells.
| Descriptor ID |
D045744
|
| MeSH Number(s) |
A11.251.210.190 A11.251.860.180
|
| Concept/Terms |
Cell Line, Tumor- Cell Line, Tumor
- Cell Lines, Tumor
- Line, Tumor Cell
- Lines, Tumor Cell
- Tumor Cell Lines
- Tumor Cell Line
|
Below are MeSH descriptors whose meaning is more general than "Cell Line, Tumor".
Below are MeSH descriptors whose meaning is more specific than "Cell Line, Tumor".
This graph shows the total number of publications written about "Cell Line, Tumor" by people in this website by year, and whether "Cell Line, Tumor" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 2002 | 0 | 1 | 1 |
| 2003 | 0 | 18 | 18 |
| 2004 | 0 | 57 | 57 |
| 2005 | 0 | 62 | 62 |
| 2006 | 1 | 57 | 58 |
| 2007 | 0 | 70 | 70 |
| 2008 | 1 | 79 | 80 |
| 2009 | 2 | 105 | 107 |
| 2010 | 0 | 88 | 88 |
| 2011 | 1 | 113 | 114 |
| 2012 | 2 | 90 | 92 |
| 2013 | 2 | 114 | 116 |
| 2014 | 0 | 130 | 130 |
| 2015 | 0 | 136 | 136 |
| 2016 | 0 | 153 | 153 |
| 2017 | 0 | 117 | 117 |
| 2018 | 0 | 143 | 143 |
| 2019 | 1 | 136 | 137 |
| 2020 | 0 | 119 | 119 |
| 2021 | 0 | 118 | 118 |
| 2022 | 0 | 41 | 41 |
| 2023 | 0 | 57 | 57 |
| 2024 | 0 | 98 | 98 |
| 2025 | 0 | 125 | 125 |
| 2026 | 0 | 74 | 74 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cell Line, Tumor" by people in Profiles.
-
Phosphorylation Protects Oncogenic RAS from LZTR1-Mediated Degradation. Blood Cancer Discov. 2026 Nov 03; 7(6):978-998.
-
Panitumumab-Based EGFR Blockade in SMARCB1-Deficient Renal Medullary Carcinoma: Preclinical Basis and Prospective Clinical Activity. Clin Cancer Res. 2026 Nov 02; 32(21):4956-4974.
-
Dysregulated AKT signaling reprograms osteosarcoma to drive selective reliance on EP300. J Exp Med. 2026 Nov 02; 223(11).
-
Citron kinase activity controls alternative splicing events that drive prostate cancer growth. Sci Adv. 2026 Oct 09; 12(41):eaee5257.
-
Targeting p300 Reverses Acidic Microenvironment-Induced PARP Inhibitor Resistance. Cancer Res. 2026 Oct 02; 86(19):4934-4954.
-
Firefox, a protein encoded by circular PVT1, is essential for MYC-driven oncogenesis. Genes Dev. 2026 Oct 01; 40(19-20):1688-1705.
-
Honeybadger, a micropeptide encoded by an alternative PVT1 transcript, is a critical negative regulator of RAS-MAPK signaling in MYC-driven tumors. Genes Dev. 2026 Oct 01; 40(19-20):1706-1723.
-
Stroke drives glioma progression through the emergence of tumor-associated astrocytes with reduced Ca2+ activity. Nat Cancer. 2026 Oct; 7(10):1610-1627.
-
CAMKV kinase drives neuroblastoma growth and acts as a novel therapeutic target. J Exp Med. 2026 Oct 05; 223(10).
-
p63 and p73 drive cutaneous squamous cell carcinoma through convergent transcriptional control of EGFR signaling. Cell Rep. 2026 Oct 27; 45(10):118030.